Search results for Bmrn

BioMarin outlines $3.825B-$3.925B 2026 revenue outlook driven by Amicus integration and 20% growth target

Alamar Biosciences: Looking For An Early Detection

Mirum Pharmaceuticals prices $600M senior notes

Is Bitmine Immersion Technologies, Inc. (BMNR) A Good Stock To Buy Now?

ResMed expects FY 2026 gross margin of 62%-63% as it plans $175M+ Q4 buybacks and targets June 1 close for $340M Noctrix...

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG

Mirum raises 2026 net product sales outlook to $660M-$680M as it targets year-end zilurgisertib launch

Matinas BioPharma receives notice from NYSE

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

Bicara (BCAX) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DateMay 11, 2026, at 8:30 a.m. ETCall participantsChief Executive Officer — Claire Mazumdar ClemonChief Medical Officer — Bill SchelmanChief Commerc...

Barinthus Biotherapeutics shareholders approve scheme of arrangement

JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT

JPMorgan Initiates ResMed (RMD) With “Overweight” Rating and A$37.6 PT

Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

May 12 2026 - BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal admin Tue, 05/12/2026 - 12:10 Big deals lead the way today, with a massive BMS partners...

Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000

This Boston biotech specializing in antibody therapies for solid tumors reported a notable insider sale during active clinical development.

Obsidian, Galera to advance cell therapy following reverse merger

The combined company will trade on the Nasdaq under the ticker OBX. It has also secured commitments for a private placement expected to deliver $350 million in gross proceeds.

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug

A BioMarin Pharmaceutical drug met just one of two main goals of a Phase 3 test in a rare inherited enzyme deficiency with no FDA-approved therapies. The drug, a fusion protein, ca...

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

Beta Bionics BBNX Q1 2026 Earnings Transcript

Image source: The Motley Fool. DateTuesday, April 21, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Sean SaintChief Financial Officer — Stephen FeiderHead of Inve...

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable

Mach Natural (MNR) Q1 2026 Earnings Transcript

Image source: The Motley Fool. DateFriday, May 8, 2026 at 10 a.m. ETCall participantsChief Executive Officer — Tom L. WardChief Financial Officer — Kevin R. WhiteTakeawaysProducti...